Human GLP-1 receptor transmembrane domain structure in complex with allosteric modulators
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
The glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR) are members of the secretin-like class B family of G-protein-coupled receptors (GPCRs) and have opposing physiological roles in insulin release and glucose homeostasis. The treatment of type 2 diabetes requires positive modulation of GLP-1R to inhibit glucagon secretion and stimulate insulin secretion in a glucose-dependent manner. Here we report crystal structures of the human GLP-1R transmembrane domain in complex with two different negative allosteric modulators, PF-06372222 and NNC0640, at 2.7 and 3.0 Å resolution, respectively. The structures reveal a common binding pocket for negative allosteric modulators, present in both GLP-1R and GCGR and located outside helices V-VII near the intracellular half of the receptor. The receptor is in an inactive conformation with compounds that restrict movement of the intracellular tip of helix VI, a movement that is generally associated with activation mechanisms in class A GPCRs. Molecular modelling and mutagenesis studies indicate that agonist positive allosteric modulators target the same general region, but in a distinct sub-pocket at the interface between helices V and VI, which may facilitate the formation of an intracellular binding site that enhances G-protein coupling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this same study, enhanced compound 2 potency was demonstrated by GLP-1R when its residue 332 was mutated to tryptophan, which is in contrast to the effect observed with this mutation on the potency of allosteric antagonists. It was postulated that enhanced compound 2 potency was caused by increased hydrophobic interactions between the receptor and the agonist with this mutation.”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [288]
In the citing paper
“Residues 328, 351 and 335 of GLP-1R were recently demonstrated to be important for compound 2 potency, as mutagenesis of these residues reduced compound 2 activity.288”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [288]
Citations
Cites
Molecular dynamics with coupling to an external bath
Berendsen, H. J. C., Postma, J. P. M., van Gunsteren, W. F., DiNola, A., & Haak, J. R. (1984) · The Journal of Chemical Physics · doi:10.1063/1.448118 · Cited by 30,700
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Canonical sampling through velocity rescaling
Bussi, G., Donadio, D., & Parrinello, M. (2007) · The Journal of Chemical Physics · doi:10.1063/1.2408420 · Cited by 18,089
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit
Pronk, S., Páll, S., Schulz, R., Larsson, P., Bjelkmar, P., Apostolov, R., Shirts, M. R., Smith, J. C., Kasson, P. M., van der Spoel, D., et al. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt055 · Cited by 7,473
PHENIX: a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2012) · International Tables for Crystallography · doi:10.1107/97809553602060000865 · Cited by 7,334
Madhavi Sastry, G., Adzhigirey, M., Day, T., Annabhimoju, R., & Sherman, W. (2013) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-013-9644-8 · Cited by 6,006
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“…critical for signal transduction, have re-energized efforts directed at development of new peptide and small-molecule GLP-1R agonists, including full and biased agonists and allosteric modulators (Figure 5) (Jazayeri et al., 2017; Song et al., 2017; Wootten et al., 2016; Zhang et al., 2017).”
BackgroundInfluentialGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“A positive allosteric modulator binds and activates GLP-1R through binding between helix V and VI, thereby creating an intercellular binding site for the G protein [423].”
BackgroundInfluentialMechanisms of signalling and biased agonism in G protein-coupled receptors
Wootten, D., Christopoulos, A., Marti-Solano, M., Babu, M. M., & Sexton, P. M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0049-3 · Cited by 724
G protein-coupled receptors: structure- and function-based drug discovery
Yang, D., Zhou, Q., Labroska, V., Qin, S., Darbalaei, S., Wu, Y., Yuliantie, E., Xie, L., Tao, H., Cheng, J., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00435-w · Cited by 632
Self-citationG protein-coupled receptors (GPCRs): advances in structures, mechanisms and drug discovery
Zhang, M., Chen, T., Lu, X., Lan, X., Chen, Z., & Lu, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01803-6 · Cited by 491
The Art and Science of Molecular Docking
Paggi, J. M., Pandit, A., & Dror, R. O. (2024) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-030222-120000 · Cited by 459
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Structural insights into G-protein-coupled receptor allostery
Thal, D. M., Glukhova, A., Sexton, P. M., & Christopoulos, A. (2018) · Nature · doi:10.1038/s41586-018-0259-z · Cited by 319
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Targeting GLP-1 receptor trafficking to improve agonist efficacy
Jones, B., Buenaventura, T., Kanda, N., Chabosseau, P., Owen, B. M., Scott, R., Goldin, R., Angkathunyakul, N., Corrêa Jr, I. R., Bosco, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03941-2 · Cited by 272
Structure of the full-length glucagon class B G-protein-coupled receptor
Zhang, H., Qiao, A., Yang, D., Yang, L., Dai, A., de Graaf, C., Reedtz-Runge, S., Dharmarajan, V., Zhang, H., Han, G. W., et al. (2017) · Nature · doi:10.1038/nature22363 · Cited by 211
Self-citationActivation of the GLP-1 receptor by a non-peptidic agonist
Zhao, P., Liang, Y.-L., Belousoff, M. J., Deganutti, G., Fletcher, M. M., Willard, F. S., Bell, M. G., Christe, M. E., Sloop, K. W., Inoue, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1902-z · Cited by 164
Self-citationDuncan, A. L., Song, W., & Sansom, M. S. P. (2020) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023411 · Cited by 158
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Self-citationTan, L., Yan, W., McCorvy, J. D., & Cheng, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00435 · Cited by 140
Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug–Target Interactions
Lu, S., & Zhang, J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01844 · Cited by 158
Full-length human GLP-1 receptor structure without orthosteric ligands
Wu, F., Yang, L., Hang, K., Laursen, M., Wu, L., Han, G. W., Ren, Q., Roed, N. K., Lin, G., Hanson, M. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14934-5 · Cited by 139
Self-citationExtending the Structural View of Class B GPCRs
de Graaf, C., Song, G., Cao, C., Zhao, Q., Wang, M.-W., Wu, B., & Stevens, R. C. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.10.003 · Cited by 144
Self-citationLigand binding at the protein–lipid interface: strategic considerations for drug design
Payandeh, J., & Volgraf, M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00240-2 · Cited by 128
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 132
The pocketome of G-protein-coupled receptors reveals previously untargeted allosteric sites
Hedderich, J. B., Persechino, M., Becker, K., Heydenreich, F. M., Gutermuth, T., Bouvier, M., Bünemann, M., & Kolb, P. (2022) · Nature Communications · doi:10.1038/s41467-022-29609-6 · Cited by 125
Chen, X., Mietlicki-Baase, E. G., Barrett, T. M., McGrath, L. E., Koch-Laskowski, K., Ferrie, J. J., Hayes, M. R., & Petersson, E. J. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b08417 · Cited by 108
Song, W., Yen, H.-Y., Robinson, C. V., & Sansom, M. S. P. (2019) · Structure · doi:10.1016/j.str.2018.10.024 · Cited by 118
G Protein–Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus
Riddy, D. M., Delerive, P., Summers, R. J., Sexton, P. M., & Langmead, C. J. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014373 · Cited by 108
“GPRC5B expressed in pancreatic islets negatively regulates insulin secretion, potentially by reducing cell viability, as shown by cytokine challenge in murine insulin-secreting MIN6 cells (Soni et al., 2013).”
BackgroundFunctional dynamics of G protein-coupled receptors reveal new routes for drug discovery
Conflitti, P., Lyman, E. R., Sansom, M. S. P., Hildebrand, P. W., Gutiérrez‐de‐Terán, H., Carloni, P., Ansell, T. B., Yuan, S., Barth, P., Robinson, A. S., et al. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01083-3 · Cited by 120
Diabesity and antidiabetic drugs
Pappachan, J. M., Fernandez, C. J., & Chacko, E. C. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.10.004 · Cited by 109
Molecular mechanisms by which GLP-1 RA and DPP-4i induce insulin sensitivity
Yaribeygi, H., Sathyapalan, T., & Sahebkar, A. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116776 · Cited by 102
Lipid-Protein Interactions Are a Unique Property and Defining Feature of G Protein-Coupled Receptors
Sejdiu, B. I., & Tieleman, D. P. (2020) · Biophysical Journal · doi:10.1016/j.bpj.2020.03.008 · Cited by 109
Molecular insights into ago-allosteric modulation of the human glucagon-like peptide-1 receptor
Cong, Z., Chen, L.-N., Ma, H., Zhou, Q., Zou, X., Ye, C., Dai, A., Liu, Q., Huang, W., Sun, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24058-z · Cited by 89
Self-citationDeepCPI: A Deep Learning-Based Framework for Large-Scale in Silico Drug Screening
Wan, F., Zhu, Y., Hu, H., Dai, A., Cai, X., Chen, L., Gong, H., Xia, T., Yang, D., Wang, M.-W., et al. (2019) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2019.04.003 · Cited by 92
Self-citationNew Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling
Tomas, A., Jones, B., & Leech, C. (2020) · Journal of Molecular Biology · doi:10.1016/j.jmb.2019.08.009 · Cited by 86
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Structure and Function of Peptide-Binding G Protein-Coupled Receptors
Wu, F., Song, G., de Graaf, C., & Stevens, R. C. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.06.022 · Cited by 92
Self-citationAllosteric modulation of G protein-coupled receptor signaling
Shen, S., Zhao, C. S., Wu, C., Sun, S., Li, Z., Yan, W. X., & Shao, Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1137604 · Cited by 87
Chemical Diversity in the G Protein-Coupled Receptor Superfamily
Vass, M., Kooistra, A. J., Yang, D., Stevens, R. C., Wang, M.-W., & de Graaf, C. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.02.004 · Cited by 87
Self-citationA combined activation mechanism for the glucagon receptor
Mattedi, G., Acosta-Gutiérrez, S., Clark, T., & Gervasio, F. L. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1921851117 · Cited by 80
Structural basis for activation of the growth hormone-releasing hormone receptor
Zhou, F., Zhang, H., Cong, Z., Zhao, L., Zhou, Q., Mao, C., Cheng, X., Shen, D., Cai, X., Ma, C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18945-0 · Cited by 79
Self-citationStructural perspective of class B1 GPCR signaling
Cong, Z., Liang, Y.-L., Zhou, Q., Darbalaei, S., Zhao, F., Feng, W., Zhao, L., Xu, H. E., Yang, D., & Wang, M.-W. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.01.002 · Cited by 80
Self-citationNew Insights into the Structure and Function of Class B1 GPCRs
Cary, B. P., Zhang, X., Cao, J., Johnson, R. M., Piper, S. J., Gerrard, E. J., Wootten, D. L., & Sexton, P. M. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac033 · Cited by 77
Singla, J., McClary, K. M., White, K. L., Alber, F., Sali, A., & Stevens, R. C. (2018) · Cell · doi:10.1016/j.cell.2018.03.014 · Cited by 71
Self-citationSzlenk, C. T., GC, J. B., & Natesan, S. (2019) · Molecular Pharmacology · doi:10.1124/mol.118.115113 · Cited by 71
Targeting the PAC1 Receptor for Neurological and Metabolic Disorders
Liao, C., de Molliens, M. P., Schneebeli, S. T., Brewer, M., Song, G., Chatenet, D., Braas, K. M., May, V., & Li, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190709092647 · Cited by 70
Self-citationWang, Y., Yu, Z., Xiao, W., Lu, S., & Zhang, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.12.001 · Cited by 71
Self-citationRecent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors
Suzuki, R., Brown, G. A., Christopher, J. A., Scully, C. C. G., & Congreve, M. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00835 · Cited by 60
Biologically active compounds and drugs in the tetrazole series
Myznikov, L. V., Владимировна, В. С., & Zevatskii, Y. É. (2021) · Chemistry of Heterocyclic Compounds · doi:10.1007/s10593-021-02897-4 · Cited by 66
Class B1 GPCR activation by an intracellular agonist
Kobayashi, K., Kawakami, K., Kusakizako, T., Tomita, A., Nishimura, M., Sawada, K., Okamoto, H. H., Hiratsuka, S., Nakamura, G., Kuwabara, R., et al. (2023) · Nature · doi:10.1038/s41586-023-06169-3 · Cited by 61
Structural basis for recognition of antihistamine drug by human histamine receptor
Peng, X., Yang, L., Liu, Z., Lou, S., Mei, S., Li, M., Chen, Z., & Zhang, H. (2022) · Nature Communications · doi:10.1038/s41467-022-33880-y · Cited by 61
Self-citationShpakov, A. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076187 · Cited by 60
A unique hormonal recognition feature of the human glucagon-like peptide-2 receptor
Sun, W., Chen, L.-N., Zhou, Q., Zhao, L.-H., Yang, D., Zhang, H., Cong, Z., Shen, D.-D., Zhao, F., Zhou, F., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00442-0 · Cited by 60
Self-citationTwo distinct domains of the glucagon-like peptide-1 receptor control peptide-mediated biased agonism
Lei, S., Clydesdale, L., Dai, A., Cai, X., Feng, Y., Yang, D., Liang, Y.-L., Koole, C., Zhao, P., Coudrat, T., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003278 · Cited by 60
Self-citationWright, S. C., Motso, A., Koutsilieri, S., Beusch, C. M., Sabatier, P., Berghella, A., Blondel-Tepaz, É., Mangenot, K., Pittarokoilis, I., Sismanoglou, D.-C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-41893-4 · Cited by 56
Yuan, X., Raniolo, S., Limongelli, V., & Xu, Y. (2018) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.8b00046 · Cited by 56
Toward an understanding of the structural basis of allostery in muscarinic acetylcholine receptors
Burger, W. A. C., Sexton, P. M., Christopoulos, A., & Thal, D. M. (2018) · The Journal of General Physiology · doi:10.1085/jgp.201711979 · Cited by 59
Saleh, N., Hucke, O., Kramer, G., Schmidt, E., Montel, F., Lipiński, R., Ferger, B., Clark, T., Hildebrand, P. W., & Tautermann, C. S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201708764 · Cited by 51
Zhang, B., Zhao, S., Yang, D., Wu, Y., Ye, X., Cao, H., Huang, X., Cai, X., Sun, W. C., Ye, N., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.9b01125 · Cited by 51
Self-citationLu, J., Piper, S. J., Zhao, P., Miller, L. J., Wootten, D. L., & Sexton, P. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158069 · Cited by 53
Structural pharmacology and mechanisms of GLP-1R signaling
Zhou, Q., Zhao, F., Zhang, Y., Yang, D., & Wang, M. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.03.003 · Cited by 53
Self-citationAnalysis of tractable allosteric sites in G protein-coupled receptors
Wakefield, A., Mason, J. S., Vajda, S., & Keserű, G. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-42618-8 · Cited by 49
miR-7 Regulates GLP-1-Mediated Insulin Release by Targeting β-Arrestin 1
Matarese, A., Gambardella, J., Lombardi, A., Wang, X., & Santulli, G. (2020) · Cells · doi:10.3390/cells9071621 · Cited by 45
GLP-1R Signaling and Functional Molecules in Incretin Therapy
Wan, W., Qin, Q., Xie, L., Zhang, H., Wu, F., Stevens, R. C., & Liu, Y. (2023) · Molecules · doi:10.3390/molecules28020751 · Cited by 44
“Due to a poor understanding of the ligand binding mode and activation mechanism prior to the first GLP-1R structure being solved in 2017 [101], high-throughput screening was adapted in many studies to identify promising candidates, followed by massive structure–activity relationship (SAR) studies to improve the chemic…”
BackgroundSelf-citationHoppe, N., Harrison, S., Hwang, S., Chen, Z.-W., Karelina, M., Deshpande, I., Suomivuori, C., Palicharla, V. R., Berry, S. P., Tschaikner, P., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-024-01223-8 · Cited by 45
Tang, K., Tang, Z., Niu, M., Kuang, Z., Xue, W., Wang, X., Liu, X., Yu, Y., Jeong, S. D., Ma, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58746-x · Cited by 46
h CALCRL mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia
Mackie, D. I., Mutairi, F. A., Davis, R. B., Kechele, D. O., Nielsen, N. R., Snyder, J. C., Caron, M. G., Kliman, H. J., Berg, J. S., Simms, J., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180528 · Cited by 45
Deep Learning Dynamic Allostery of G-Protein-Coupled Receptors
Do, H. N., Wang, J., & Miao, Y. (2023) · JACS Au · doi:10.1021/jacsau.3c00503 · Cited by 42
Current understanding of the structure and function of family B GPCRs to design novel drugs
Karageorgos, V., Venihaki, M., Sakellaris, S., Pardalos, M., Kontakis, G. M., Matsoukas, M., Gravanis, A., Margioris, A. N., & Liapakis, G. (2018) · HORMONES · doi:10.1007/s42000-018-0009-5 · Cited by 45
Chepurny, O. G., Matsoukas, M.-T., Liapakis, G., Leech, C. A., Milliken, B. T., Doyle, R. P., & Holz, G. G. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005682 · Cited by 41
Structural Basis for Allosteric Modulation of Class B G Protein–Coupled Receptors
Wootten, D. L., & Miller, L. J. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023301 · Cited by 42
Malik, F., & Li, Z. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15446 · Cited by 41
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor
Wang, X.-S., Heinz, B. A., Qian, Y., Carter, J. H., Gadski, R. A., Beavers, L. S., Little, S. P., Yang, C. R., Beck, J. P., Hao, J., et al. (2018) · Molecular Pharmacology · doi:10.1124/mol.118.112649 · Cited by 40
Gabe, M. B. N., van der Velden, W. J. C., Smit, F. X., Gasbjerg, L. S., & Rosenkilde, M. M. (2020) · Peptides · doi:10.1016/j.peptides.2019.170224 · Cited by 37
Fang, Z., Chen, S., Pickford, P., Broichhagen, J., Hodson, D. J., Corrêa, I. R., Kumar, S., Görlitz, F., Dunsby, C., French, P. M. W., et al. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00022 · Cited by 38
Molecular Pharmacology of Class F Receptor Activation
Kozielewicz, P., Turku, A., & Schulte, G. (2019) · Molecular Pharmacology · doi:10.1124/mol.119.117986 · Cited by 42
GPCR Allosteric Modulator Discovery
Wu, Y., Tong, J., Ding, K., Zhou, Q., & Zhao, S. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_10 · Cited by 39
Self-citationvan der Velden, W. J. C., Smit, F. X., Christiansen, C. B., Møller, T. C., Hjortø, G. M., Larsen, O., Schiellerup, S. P., Bräuner‐Osborne, H., Holst, J. J., Hartmann, B., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00193 · Cited by 42
Gong, B., Li, C., Shi, Z., Wang, F., Dai, R., Chen, G., & Su, H. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1675552 · Cited by 36
“Moreover, GLP-1R expression has also been detected in several components of the immune system, such as macrophages, lymphocytes, and invariant natural killer T (iNKT) cells (Song et al., 2017).”
A framework for Frizzled-G protein coupling and implications to the PCP signaling pathways
(2024) · doi:10.1038/s41421-023-00627-y · Cited by 36
Self-citationWoolley, M. J., Reynolds, C. A., Simms, J., Walker, C. S., Mobarec, J. C., Garelja, M. L., Conner, A. C., Poyner, D. R., & Hay, D. L. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.07.005 · Cited by 37
Molecular Mechanisms of PTH/PTHrP Class B GPCR Signaling and Pharmacological Implications
Vilardaga, J., Clark, L. J., White, A. D., Sutkevičiu̅tė, I., Lee, J. Y., & Bahar, İ. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnac032 · Cited by 33
Conjugation with glucagon like peptide-1 enables targeted protein degradation
Zhu, L., Zhou, Y., Zhang, B., Luo, Y., Chen, F., Yan, X., Cai, Y., Jiang, L., & Ge, J. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106908 · Cited by 31
The GLP-1R as a model for understanding and exploiting biased agonism in next-generation medicines
Douros, J. D., Mokrosiński, J., & Finan, B. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0226 · Cited by 31
Sebastiani, G., Ceccarelli, E., Castagna, M. G., & Dotta, F. (2018) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2018.02.005 · Cited by 32
Deng, S., Chen, Z., & Shi, Y. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01486-8 · Cited by 30
Lau, C. H. Y., Hunter, M. J., Stewart, A. G., Perozo, E., & Vandenberg, J. I. (2018) · The Journal of Physiology · doi:10.1113/jp274888 · Cited by 30
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction
Ciancetta, A., Gill, A. K., Ding, T., Karlov, D. S., Chalhoub, G., McCormick, P. J., & Tikhonova, I. G. (2021) · ACS Central Science · doi:10.1021/acscentsci.1c00802 · Cited by 29
Lemos, A., Melo, R., Preto, A. J., de Almeida, J. G., Moreira, I. S., & Cordeiro, M. N. D. S. (2018) · Current Neuropharmacology · doi:10.2174/1570159x16666180308161642 · Cited by 29
Molecular Basis of Class B GPCR Selectivity for the Neuropeptides PACAP and VIP
Liao, C., Remington, J. M., May, V., & Li, J. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.644644 · Cited by 33
Zhang, J., Bai, Q., Pérez‐Sánchez, H., Shang, S., An, X., & Yao, X. (2019) · Physical Chemistry Chemical Physics · doi:10.1039/c9cp00080a · Cited by 28
A non-canonical mechanism of GPCR activation
Powers, A. S., Khan, A. A., Paggi, J. M., Latorraca, N. R., Souza, S., Salvo, J. D., Lu, J., Soisson, S. M., Johnston, J. M., Weinglass, A. B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54103-6 · Cited by 26
Kupnicka, P., Król, M., Żychowska, J., Łagowski, R., Prajwos, E., Surówka, A., & Chlubek, D. (2024) · Pharmaceuticals · doi:10.3390/ph17111470 · Cited by 26
Drug-induced diabetes type 2: In silico study involving class B GPCRs
Latek, D., Rutkowska, E. E., Niewieczerzał, S., & Cielecka‐Piontek, J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0208892 · Cited by 30
Liu, Q., Garg, P., Hasdemir, B., Wang, L., Tuscano, E., Sever, E. N., Rivera, E. K., Hernandez, A. G. L., Yuan, T. Z., Kwan, E., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893425 · Cited by 24
Combining structural and coevolution information to unveil allosteric sites
Sala, G. L., Pfleger, C., Käck, H., Wissler, L., Nevin, P., Böhm, K., Janet, J. P., Schimpl, M., Stubbs, C. J., Vivo, M. D., et al. (2023) · Chemical Science · doi:10.1039/d2sc06272k · Cited by 24
Liu, N., Cui, X. Y., Yan, W., Guo, T., Wang, Z., Wei, X., Sun, Y., Liu, J., Cheng, X., Ma, W., et al. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.100968 · Cited by 26
A benchmark study of loop modeling methods applied to G protein-coupled receptors
Wink, L. H., Baker, D. L., Cole, J. A., & Parrill, A. L. (2019) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-019-00196-x · Cited by 24
Investigating GIPR (ant)agonism: A structural analysis of GIP and its receptor
Smit, F. X., van der Velden, W. J. C., Kizilkaya, H. S., Nørskov, A., Lückmann, M., Hansen, T. N., Sparre-Ulrich, A. H., Qvotrup, K., Frimurer, T. M., & Rosenkilde, M. M. (2021) · Structure · doi:10.1016/j.str.2021.04.001 · Cited by 24
Allosteric Modulators Enhancing GLP-1 Binding to GLP-1R via a Transmembrane Site
Wang, J., Yang, D., Cheng, X., Yang, L., Wang, Z., Dai, A., Cai, X., Zhang, C., Yuliantie, E., Liu, Q., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00552 · Cited by 24
Self-citationPAC1 Receptors: Shapeshifters in Motion
Liao, C., May, V., & Li, J. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1132-0 · Cited by 23
Tian, R. L., Yin, J., Yao, Q., Wang, T., Chen, J., Liang, Q., Li, Q., & Zhao, X. (2022) · Analytical Chemistry · doi:10.1021/acs.analchem.2c01210 · Cited by 22
Redij, T., Chaudhari, R. R., Li, Z., Hua, X., & Li, Z. (2019) · ACS Omega · doi:10.1021/acsomega.8b03052 · Cited by 23
Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide‑1 Receptor
Bird, G. H., Fu, A., Escudero, S., Godes, M., Opoku-Nsiah, K., Wales, T. E., Cameron, M. D., Engen, J. R., Danial, N. N., & Walensky, L. D. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00308 · Cited by 22
Metadata
- Authors
- Song, G., Yang, D., Wang, Y., de Graaf, C., Zhou, Q., Jiang, S., Liu, K., Cai, X., Dai, A., Lin, G., Liu, D., Wu, F., Wu, Y., Zhao, S., Ye, L., Han, G. W., Lau, J., Wu, B., Hanson, M. A., Liu, Z.-J., Wang, M.-W., & Stevens, R. C.
- Affiliations
- ShanghaiTech University (CN)
- Chinese Academy of Sciences (CN)
- Fudan University (CN)
- University of Southern California (US)
- Novo Nordisk (Denmark) (DK)
- Kunming Medical University (CN)
- Corresponding author
- Liu, Zhi-Jie
- Wang, Ming-Wei
- Stevens, Raymond C.
- ORCID
- Venue
- Nature
- Published
- 2017-05-17
- Volume
- 546
- Issue
- 7657
- Pages
- 312-315
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2616258954
- Cited by
- 241
- References
- 50
- Citations by year
- 2026: 12 · 2025: 23 · 2024: 18 · 2023: 22 · 2022: 23 · 2021: 27 · 2020: 32 · 2019: 38 · 2018: 31 · 2017: 15
- FWCI
- 13.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- VU Research Portal (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- GLP-1 receptor, transmembrane domain structure, negative allosteric modulators, receptor activation mechanism, class B GPCRs, glucagon receptor, G protein coupling, type 2 diabetes, peptide agonists, glucagon-like peptide-1
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Protein Domains, Glucagon-Like Peptide-1 Receptor Agonists, Allosteric Regulation, Allosteric Site, Amino Acid Sequence, Aminopyridines, Benzamides, Humans, Models, Molecular, Phenylurea Compounds, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.